MoneyWorks4Me

GlaxoSmithKline Pharmaceuticals informs board meeting

03 May 2021 Evaluate

Pursuant to clause 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015 (LODR), GlaxoSmithKline Pharmaceuticals has informed that a meeting of the Board of Directors of the Company will be held on Tuesday, 18th May 2021, to consider amongst other things, approval of audited financial results (Standalone & Consolidated) for the quarter / year ended 31st March 2021 and to recommend dividend, if any, on the equity shares of the Company.

The above information is a part of company’s filings submitted to BSE.

Glaxosmithkline Phar Share Price

3027.50 47.45 (1.59%)
26-Aug-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1901.00
Dr. Reddys Labs. 1186.40
Cipla 1408.40
Lupin 2191.20
Zydus Lifesciences 1147.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: